BioLargo, Inc.
BioLargo, Inc.
Your view on BLGO
Overview
What the company does, where it operates, and who runs it.
About BioLargo, Inc.
- Industry
- Chemicals - Specialty
- Sector
- Basic Materials
- CEO
- Dennis Calvert
- Headquarters
- 14921 Chestnut Street, Westminster, CA, US
- Industry
- Chemicals - Specialty
- Sector
- Basic Materials
- CEO
- Dennis Calvert
- Headquarters
- 14921 Chestnut Street, Westminster, CA, US
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control.
It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services.
The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioLargo, Inc., and the rating behind it. BLGO last traded at $0.18; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioLargo, Inc.. Starting points for BioLargo, Inc.: EPS -$0.05, beta -0.04 — an Chemicals - Specialty name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioLargo, Inc.. BioLargo, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioLargo, Inc.. Trailing twelve-month EPS for BioLargo, Inc. stands at -$0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioLargo, Inc.. BioLargo, Inc. has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioLargo, Inc. valued side by side against its closest peers. BioLargo, Inc. is measured against Chemicals - Specialty peers within the Basic Materials sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioLargo, Inc., and how their positions are changing. At a $55.0M market value, institutional positions materially move BioLargo, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioLargo, Inc. executives and directors. Shares of BioLargo, Inc. have traded between $0.14 and $0.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioLargo, Inc.. BioLargo, Inc. is a $55.0M Basic Materials company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioLargo, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioLargo, Inc.. Coverage tracks BioLargo, Inc. within Chemicals - Specialty (Basic Materials). Press releases and market coverage, newest first.